INSM Biotech · Respiratory disease · Commercial biotech · Rare disease · Thesis updated July 19, 2026

A hot launch, priced for perfection

BRINSUPRI has quickly become Insmed's largest product, with $207.9 million in Q1 2026 revenue.
ARIKAYCE added $98.1 million in Q1 2026 and may get a wider MAC lung disease label after positive ENCORE data.
Management said BRINSUPRI grew 44% from the prior quarter, with more than 5,000 cumulative prescribers.
The bear case is valuation: the stock needs a clean launch, steady ARIKAYCE sales, and good TPIP data.
Two brensocatib expansion studies failed, so more of the future now rests on TPIP and label expansion work.

01 Running thesis

The launch changed the story

Insmed used to look like a one-product biotech waiting on a big approval. That changed after BRINSUPRI, an oral medicine for bronchiectasis, launched in the US in August 2025. In Q1 2026, BRINSUPRI revenue was $207.9 million, or 68.0% of product revenue. ARIKAYCE, the older inhaled antibiotic for MAC lung disease, brought in $98.1 million.

The bull case is simple. BRINSUPRI is showing fast early adoption in a disease with few good options. Management said Q1 2026 BRINSUPRI sales grew 44% from the prior quarter, cumulative writers topped 5,000, and 6-month continuation was tracking slightly above a 70% oral-medicine benchmark. That points to real demand, not only launch noise.

ARIKAYCE also matters. Positive ENCORE trial data in March 2026 supports a planned sNDA, which is a request to the FDA to expand an approved drug's label, in the second half of 2026. If approved, ARIKAYCE could reach all MAC lung disease patients, not only its narrower current group.

The bear case is the price and the pipeline. Finn's valuation score is low, which means the stock already seems to expect a lot. Brensocatib failed in CRSsNP and HS, two other disease areas, so Insmed has less room for pipeline mistakes. TPIP, an inhaled treprostinil prodrug, is now a key future driver.

May 2026▲Q1 2026 commentary showed BRINSUPRI still growing fast, with 44% sequential growth and more than 5,000 cumulative prescribers. TPIP open-label extension dosing color also looked supportive before the Q3 2026 data readout.

May 2026→The Q1 2026 filing confirmed positive ENCORE data and a planned ARIKAYCE sNDA in H2 2026. It also confirmed the HS brensocatib program was stopped after the Phase 2b CEDAR study failed.

Feb 2026▲The 2025 Form 10-K showed Insmed had become a two-product commercial company. Full-year 2025 product revenue was $606.4 million, helped by $172.7 million of US BRINSUPRI sales after FDA approval.

Oct 2025▲The Q3 2025 filing marked the first major BRINSUPRI launch proof point after US approval. It also made clear that failed CRSsNP work reduced the number of brensocatib expansion paths.

Aug 2025▲The Q2 2025 filing showed positive TPIP Phase 2b data in PAH and continued ARIKAYCE growth. A large stock offering also reduced near-term financing pressure before the brensocatib launch.

May 2025→The Q1 2025 filing kept the thesis on track, with ARIKAYCE revenue up 22.9% year over year. The main focus stayed on the upcoming brensocatib FDA decision.

Feb 2025▲The FDA accepted the brensocatib NDA with priority review and set an August 12, 2025 target action date. That shifted the main risk from approval timing toward launch execution.

Oct 2024→The initial thesis framed Insmed as a growing ARIKAYCE business with brensocatib as the key late-stage value driver. Main risks were regulatory approval, launch execution, and third-party manufacturing.

02 Business model

Two lung drugs pay the bills

Insmed makes money by selling prescription drugs through specialty pharmacies and distributors. Almost all current revenue comes from the Respiratory area, through BRINSUPRI and ARIKAYCE.

BRINSUPRI is the growth engine. It is a once-daily oral DPP1 inhibitor for bronchiectasis, a long-term lung disease where damaged airways lead to flare-ups and infection risk. Its edge is being first to market for that use, plus the size of the untreated need.

ARIKAYCE is the established product. It is an inhaled antibiotic for MAC lung disease, a hard-to-treat lung infection. Insmed's Pulmovance liposomal delivery technology helps deliver the drug to the lungs.

The model can break in plain ways. Payers may tighten access, doctors may slow new starts, patients may stop therapy, or contract manufacturers may fail to supply enough product. Insmed also still spends heavily on research and sales, so profits are not guaranteed.

03 Product portfolio

What Insmed is selling and testing

Growth engine

BRINSUPRI

BRINSUPRI is an oral, once-daily drug for bronchiectasis. It launched in the US in Q3 2025 and became the largest product by Q1 2026 revenue.

Cash cow

ARIKAYCE

ARIKAYCE is an inhaled antibiotic for adult MAC lung disease. Positive ENCORE data supports a planned US label expansion filing in the second half of 2026.

Option

TPIP

TPIP is an inhaled treprostinil prodrug being tested in pulmonary blood pressure diseases tied to lung disease and PAH. Management said some open-label extension patients reached doses above 640 mcg, with several reaching 1,280 mcg.

Option

INS1148

INS1148 is a Phase 2-ready antibody acquired in December 2025. Insmed plans to study it in interstitial lung disease and asthma.

Option

INS1201 and INS1202 gene therapy

These early gene therapy programs target Duchenne muscular dystrophy and ALS. Both are in Phase 1, so they are still high-risk, long-term bets.

Steady

Stopped brensocatib expansions

Insmed stopped brensocatib work in CRSsNP after a failed Phase 2b BiRCh study and in HS after a failed Phase 2b CEDAR study. That narrows the growth story outside bronchiectasis.

04 Business segments

Revenue is now BRINSUPRI-led

BRINSUPRI68%growing fast

ARIKAYCE32%flat

The mix is for the three months ended March 31, 2026. Product revenue was split between BRINSUPRI at 68.0% and ARIKAYCE at 32.0%, with the United States making up 88.3% of total revenue.

05 Risk factors

What could go wrong

BRINSUPRI launch slows after early demand

High impact · Medium odds

New drugs often get a first wave from patients who were waiting for treatment. The key question is whether BRINSUPRI can keep adding new patients after that wave fades. A slowdown would matter because BRINSUPRI was already 68.0% of Q1 2026 product revenue.

We watchQuarterly BRINSUPRI revenue, new patient starts, prescriber count, payer approval rates, and 6-month continuation.

ARIKAYCE loses focus

Medium impact · Medium odds

The internal thesis flags a 2.2% year-over-year dip in US ARIKAYCE revenue in Q1 2026. That could be a short-term issue, or it could mean the sales team and doctors are shifting attention to BRINSUPRI. The planned label expansion could offset this, but only if the filing and review go well.

We watchUS ARIKAYCE revenue trends and the planned H2 2026 sNDA submission for all MAC lung disease patients.

TPIP data disappoints

High impact · Medium odds

Two brensocatib expansion programs have already failed, which puts more weight on TPIP. TPIP has several possible lung and pulmonary pressure uses, but the value still depends on clinical data and trial design. If Phase 3 trials are weak or delayed, the long-term story gets thinner.

We watchQ3 2026 TPIP Phase 2b open-label extension data and Phase 3 start details for PPF and IPF-related plans.

Regulators or payers push back

High impact · Medium odds

Insmed needs regulators to accept wider use of ARIKAYCE and needs payers to keep covering BRINSUPRI. Even a good drug can miss sales hopes if insurers add paperwork, deny claims, or force patients to try other drugs first.

We watchFDA updates on the ARIKAYCE sNDA, Japan regulatory news for brensocatib, and reported payer approval rates.

Outside manufacturers stumble

Medium impact · Low odds

Insmed does not own its own manufacturing sites and relies on a limited number of contract manufacturers. A quality issue or supply delay could hurt both commercial sales and clinical trials.

We watchAny filing language about supply constraints, CMO quality issues, or delayed product shipments.

Spending stays ahead of cash generation

Medium impact · Medium odds

Insmed has a history of losses and still funds a large sales force and late-stage research program. BRINSUPRI improves the cash picture, but the company may still need capital if trials expand or launches cost more than expected.

We watchOperating loss, cash balance, R&D spending, SG&A spending, and any new debt or equity financing.

06 Quick answers

In one breath

What does Insmed do?

Insmed develops and sells medicines for serious lung diseases and rare diseases. Its main products are BRINSUPRI for bronchiectasis and ARIKAYCE for MAC lung disease.

Why is BRINSUPRI important to INSM stock?

BRINSUPRI is now Insmed's biggest product by revenue. In Q1 2026 it produced $207.9 million, so investors are watching whether early demand turns into a durable business.

What is the next big catalyst for Insmed?

The next items to watch are ongoing BRINSUPRI launch metrics, the ARIKAYCE sNDA filing expected in the second half of 2026, and TPIP open-label extension data expected in Q3 2026.

Why is Finn cautious on valuation?

Insmed has strong growth signs, but the market price appears to assume a lot of success. The stock needs BRINSUPRI to keep growing, ARIKAYCE to hold up, and TPIP to deliver useful data.